market-trends is the sole category represented across all 1 tracked stories. Ameluz is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Biofrontera Inc.
market-trends is the sole category represented across all 1 tracked stories. Ameluz is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.9. We currently track 1 Healthcare story that mention Biofrontera Inc., all published on March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Biofrontera Inc.. Shared-story counts are live from our verified record — not editorial picks.
Biofrontera Inc. (Nasdaq: BFRI) has reported record-breaking financial results for the fourth quarter and full year 2025, signaling a major milestone in the commercial adoption of its photodynamic therapy (PDT) solutions. The company is leveraging increased market penetration of its flagship product, Ameluz, and its proprietary BF-RhodoLED lamps across U.S. dermatology practices.
